Researchers at Rajiv Gandhi Centre for Biotechnology (RGCB), Thiruvananthapuram are in the final stages of developing a kit that promises to help detect SARS CoVID-19 infection as early as four days post-infection of the virus.
The kit will be able to detect two types of antibodies – Immunoglobulin M (IgM) and Immunoglobulin G (IgG). IgM is the first antibody that appears in human body when it is exposed to a virus or any other antigen. Presence of IgG antibody in the body, in contrast, is indicative of an individual’s immune status to particular pathogens.
IgM is the first antibody that appears in human body when it is exposed to a virus or any other antigen.
Thus, if a person is found to have IgM antibodies even while being asymptomatic, it can be taken that he or she is infected. The person can then be isolated and sent for treatment. However, if someone is found to have IgG antibodies, it can be considered that the person has already had the infection and would be immune to new infections.
This kit is being developed in collaboration with uBIO technologies, which is a company incubated at RGCB’s BioNest facility at Kochi. The company has been producing diagnostic kits and other such devices for DRDO and other organisations and has been exporting its products to over 25 countries. India Science Wire
Source: Vigyan Prasar
You may also like
-
A smart cancer drug activating primarily in cancer cells, could replace chemotherapy
-
IIT Mandi Turns Sea Urchin Geometry Into an Antibiotic-Free Defence for 3D-Printed Bone Implants
-
Aheesa’s VIHAAN Achieves First-Pass Silicon, Advancing India’s Indigenous Broadband Chip Effort
-
India’s Space Sovereignty: Start-Ups, Human Spaceflight and Next-Generation Launch Systems Drive a New Era
-
New Computer Model can Help Trace Magnetic Energy Builds Up & Forecast Impact of Resulting CMEs
